Segment disclosures

Company overview

NIAGEN BIOSCIENCE, INC.

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

128 dimension combinations 778 retained observations 14 reported periods Partial retained history

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Operating Segments · Analytical Reference Standards And Services Segment

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-300 USD20260804Open filing evidence
2026-01-01 – 2026-06-30423000 USD20260804Open filing evidence
2026-01-01 – 2026-03-31423000 USD20260506Open filing evidence
2025-07-01 – 2025-09-30772000 USD20251104Open filing evidence
2025-01-01 – 2025-09-302382000 USD20251104Open filing evidence
2025-04-01 – 2025-06-30799000 USD20260804Open filing evidence
2025-01-01 – 2025-06-301610000 USD20260804Open filing evidence
2025-01-01 – 2025-03-31811000 USD20260506Open filing evidence
2024-07-01 – 2024-09-30784000 USD20251104Open filing evidence
2024-01-01 – 2024-09-302289000 USD20251104Open filing evidence
2024-04-01 – 2024-06-30791000 USD20250806Open filing evidence
2024-01-01 – 2024-06-301505000 USD20250806Open filing evidence
2024-01-01 – 2024-03-31714000 USD20250507Open filing evidence
2023-07-01 – 2023-09-30671000 USD20241031Open filing evidence
2023-01-01 – 2023-09-302198000 USD20241031Open filing evidence
2023-04-01 – 2023-06-30728000 USD20230809Open filing evidence
2023-01-01 – 2023-06-301527000 USD20230809Open filing evidence

Operating Segments · Consumer Products Segment

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-3024162000 USD20260804Open filing evidence
2026-01-01 – 2026-06-3046575000 USD20260804Open filing evidence
2026-01-01 – 2026-03-3122413000 USD20260506Open filing evidence
2025-07-01 – 2025-09-3026017000 USD20251104Open filing evidence
2025-01-01 – 2025-09-3070217000 USD20251104Open filing evidence
2025-04-01 – 2025-06-3022699000 USD20260804Open filing evidence
2025-01-01 – 2025-06-3044200000 USD20260804Open filing evidence
2025-01-01 – 2025-03-3121501000 USD20260506Open filing evidence
2024-07-01 – 2024-09-3018123000 USD20251104Open filing evidence
2024-01-01 – 2024-09-3054121000 USD20251104Open filing evidence
2024-04-01 – 2024-06-3018647000 USD20250806Open filing evidence
2024-01-01 – 2024-06-3035998000 USD20250806Open filing evidence
2024-01-01 – 2024-03-3117351000 USD20250507Open filing evidence
2023-07-01 – 2023-09-3017400000 USD20241031Open filing evidence
2023-01-01 – 2023-09-3051924000 USD20241031Open filing evidence
2023-04-01 – 2023-06-3016891000 USD20240807Open filing evidence
2023-01-01 – 2023-06-3034524000 USD20240807Open filing evidence

Operating Segments · Ingredients Segment

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-305387000 USD20260804Open filing evidence
2026-01-01 – 2026-06-3013951000 USD20260804Open filing evidence
2026-01-01 – 2026-03-318564000 USD20260506Open filing evidence
2025-07-01 – 2025-09-307197000 USD20251104Open filing evidence
2025-01-01 – 2025-09-3022985000 USD20251104Open filing evidence
2025-04-01 – 2025-06-307619000 USD20260804Open filing evidence
2025-01-01 – 2025-06-3015788000 USD20260804Open filing evidence
2025-01-01 – 2025-03-318169000 USD20260506Open filing evidence
2024-07-01 – 2024-09-306673000 USD20251104Open filing evidence
2024-01-01 – 2024-09-3014062000 USD20251104Open filing evidence
2024-04-01 – 2024-06-303301000 USD20250806Open filing evidence
2024-01-01 – 2024-06-307389000 USD20250806Open filing evidence
2024-01-01 – 2024-03-314088000 USD20250507Open filing evidence
2023-07-01 – 2023-09-301424000 USD20241031Open filing evidence
2023-01-01 – 2023-09-308252000 USD20241031Open filing evidence
2023-04-01 – 2023-06-302704000 USD20230809Open filing evidence
2023-01-01 – 2023-06-306828000 USD20230809Open filing evidence

Operating Segments · Pharmaceuticals Segment

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:PharmaceuticalsSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-300 USD20260804Open filing evidence
2026-01-01 – 2026-06-300 USD20260804Open filing evidence
2026-01-01 – 2026-03-310 USD20260506Open filing evidence
2025-04-01 – 2025-06-300 USD20260804Open filing evidence
2025-01-01 – 2025-06-300 USD20260804Open filing evidence
2025-01-01 – 2025-03-310 USD20260506Open filing evidence

Operating Segments · Analytical Reference Standards And Services Segment

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-313076000 USD20260304Open filing evidence
2024-01-01 – 2024-12-313011000 USD20260304Open filing evidence
2023-01-01 – 2023-12-312905000 USD20250304Open filing evidence

Operating Segments · Consumer Products Segment

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:ConsumerProductsSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-3197672000 USD20260304Open filing evidence
2024-01-01 – 2024-12-3176772000 USD20260304Open filing evidence
2023-01-01 – 2023-12-3169528000 USD20250304Open filing evidence

Operating Segments · Ingredients Segment

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:IngredientsSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-3128675000 USD20260304Open filing evidence
2024-01-01 – 2024-12-3119814000 USD20260304Open filing evidence
2023-01-01 – 2023-12-3111137000 USD20250304Open filing evidence

Operating Segments · Pharmaceuticals Segment

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:PharmaceuticalsSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-310 USD20260304Open filing evidence
2024-01-01 – 2024-12-310 USD20260304Open filing evidence

Analytical Reference Standards And Services Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-09-30423000 USD20261104Open filing evidence
2026-04-01 – 2026-06-300 USD20260804Open filing evidence
2026-01-01 – 2026-06-30423000 USD20260804Open filing evidence
2026-01-01 – 2026-03-31423000 USD20260506Open filing evidence
2025-07-01 – 2025-09-30772000 USD20261104Open filing evidence
2025-01-01 – 2025-09-302382000 USD20261104Open filing evidence
2025-04-01 – 2025-06-30799000 USD20260804Open filing evidence
2025-01-01 – 2025-06-301610000 USD20260804Open filing evidence
2025-01-01 – 2025-03-31811000 USD20260506Open filing evidence
2024-07-01 – 2024-09-30784000 USD20251104Open filing evidence
2024-01-01 – 2024-09-302289000 USD20251104Open filing evidence
2024-04-01 – 2024-06-30791000 USD20250806Open filing evidence
2024-01-01 – 2024-06-301505000 USD20250806Open filing evidence
2024-01-01 – 2024-03-31714000 USD20250507Open filing evidence
2023-07-01 – 2023-09-30671000 USD20241031Open filing evidence
2023-01-01 – 2023-09-302198000 USD20241031Open filing evidence
2023-04-01 – 2023-06-30728000 USD20240807Open filing evidence
2023-01-01 – 2023-06-301527000 USD20240807Open filing evidence

Analytical Reference Standards And Services Segment · Operating Segments

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-09-30423000 USD20261104Open filing evidence
2025-07-01 – 2025-09-30772000 USD20261104Open filing evidence
2025-01-01 – 2025-09-302382000 USD20261104Open filing evidence
2024-04-01 – 2024-06-30791000 USD20240807Open filing evidence
2024-01-01 – 2024-06-301505000 USD20240807Open filing evidence

Analytical Reference Standards And Services Segment · Consulting And Other

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdcx:ConsultingAndOtherMember
PeriodValueUnitFiledEvidence
2026-01-01 – 2026-03-3112000 USD20260506Open filing evidence
2025-07-01 – 2025-09-3015000 USD20251104Open filing evidence
2025-01-01 – 2025-09-3055000 USD20251104Open filing evidence
2025-04-01 – 2025-06-3027000 USD20250806Open filing evidence
2025-01-01 – 2025-06-3040000 USD20250806Open filing evidence
2025-01-01 – 2025-03-3113000 USD20260506Open filing evidence
2024-07-01 – 2024-09-3025000 USD20251104Open filing evidence
2024-01-01 – 2024-09-3094000 USD20251104Open filing evidence
2024-04-01 – 2024-06-3036000 USD20250806Open filing evidence
2024-01-01 – 2024-06-3069000 USD20250806Open filing evidence
2024-01-01 – 2024-03-3133000 USD20250507Open filing evidence
2023-07-01 – 2023-09-3017000 USD20241031Open filing evidence
2023-01-01 – 2023-09-3076000 USD20241031Open filing evidence

Analytical Reference Standards And Services Segment · Food Grade NIAGEN

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdcx:FoodGradeNIAGENMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-03-310 USD20260506Open filing evidence
2025-07-01 – 2025-09-300 USD20261104Open filing evidence
2025-01-01 – 2025-09-300 USD20261104Open filing evidence
2025-04-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-03-310 USD20260506Open filing evidence
2024-07-01 – 2024-09-300 USD20251104Open filing evidence
2024-01-01 – 2024-09-300 USD20251104Open filing evidence
2024-04-01 – 2024-06-300 USD20250806Open filing evidence
2024-01-01 – 2024-06-300 USD20250806Open filing evidence
2024-01-01 – 2024-03-310 USD20250507Open filing evidence
2023-07-01 – 2023-09-300 USD20241031Open filing evidence
2023-01-01 – 2023-09-300 USD20241031Open filing evidence

Analytical Reference Standards And Services Segment · NIAGEN Ingredient

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdcx:NIAGENIngredientMember
PeriodValueUnitFiledEvidence
2024-04-01 – 2024-06-300 USD20240807Open filing evidence
2024-01-01 – 2024-06-300 USD20240807Open filing evidence

Analytical Reference Standards And Services Segment · NIAGEN Related

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdcx:NIAGENRelatedMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-03-310 USD20260506Open filing evidence
2025-07-01 – 2025-09-300 USD20261104Open filing evidence
2025-01-01 – 2025-09-300 USD20261104Open filing evidence
2025-04-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-03-310 USD20260506Open filing evidence
2024-07-01 – 2024-09-300 USD20251104Open filing evidence
2024-01-01 – 2024-09-300 USD20251104Open filing evidence
2024-04-01 – 2024-06-300 USD20250806Open filing evidence
2024-01-01 – 2024-06-300 USD20250806Open filing evidence
2024-01-01 – 2024-03-310 USD20250507Open filing evidence
2023-07-01 – 2023-09-300 USD20241031Open filing evidence
2023-01-01 – 2023-09-300 USD20241031Open filing evidence

Analytical Reference Standards And Services Segment · Other Goods And Services

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdcx:OtherGoodsAndServicesMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-09-30423000 USD20261104Open filing evidence
2026-01-01 – 2026-03-31423000 USD20260506Open filing evidence
2025-07-01 – 2025-09-30772000 USD20261104Open filing evidence
2025-01-01 – 2025-09-302382000 USD20261104Open filing evidence
2025-04-01 – 2025-06-30799000 USD20250806Open filing evidence
2025-01-01 – 2025-06-301610000 USD20250806Open filing evidence
2025-01-01 – 2025-03-31811000 USD20260506Open filing evidence
2024-07-01 – 2024-09-30784000 USD20251104Open filing evidence
2024-01-01 – 2024-09-302289000 USD20251104Open filing evidence
2024-04-01 – 2024-06-30791000 USD20250806Open filing evidence
2024-01-01 – 2024-06-301505000 USD20250806Open filing evidence
2024-01-01 – 2024-03-31714000 USD20250507Open filing evidence
2023-07-01 – 2023-09-30671000 USD20241031Open filing evidence
2023-01-01 – 2023-09-302198000 USD20241031Open filing evidence

Analytical Reference Standards And Services Segment · Other Ingredients

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdcx:OtherIngredientsMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-03-310 USD20260506Open filing evidence
2025-07-01 – 2025-09-300 USD20261104Open filing evidence
2025-01-01 – 2025-09-300 USD20261104Open filing evidence
2025-04-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-03-310 USD20260506Open filing evidence
2024-07-01 – 2024-09-300 USD20251104Open filing evidence
2024-01-01 – 2024-09-300 USD20251104Open filing evidence
2024-04-01 – 2024-06-300 USD20250806Open filing evidence
2024-01-01 – 2024-06-300 USD20250806Open filing evidence
2024-01-01 – 2024-03-310 USD20250507Open filing evidence
2023-07-01 – 2023-09-300 USD20241031Open filing evidence
2023-01-01 – 2023-09-300 USD20241031Open filing evidence

Analytical Reference Standards And Services Segment · Pharmaceutical Grade NIAGEN

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdcx:PharmaceuticalGradeNIAGENMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-03-310 USD20260506Open filing evidence
2025-07-01 – 2025-09-300 USD20261104Open filing evidence
2025-01-01 – 2025-09-300 USD20261104Open filing evidence
2025-04-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-03-310 USD20260506Open filing evidence
2024-07-01 – 2024-09-300 USD20251104Open filing evidence
2024-01-01 – 2024-09-300 USD20251104Open filing evidence
2024-01-01 – 2024-03-310 USD20250507Open filing evidence
2023-07-01 – 2023-09-300 USD20241031Open filing evidence
2023-01-01 – 2023-09-300 USD20241031Open filing evidence

Analytical Reference Standards And Services Segment · Reference Standards

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdcx:ReferenceStandardsMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-09-30411000 USD20261104Open filing evidence
2026-01-01 – 2026-03-31411000 USD20260506Open filing evidence
2025-07-01 – 2025-09-30757000 USD20261104Open filing evidence
2025-01-01 – 2025-09-302327000 USD20261104Open filing evidence
2025-04-01 – 2025-06-30772000 USD20250806Open filing evidence
2025-01-01 – 2025-06-301570000 USD20250806Open filing evidence
2025-01-01 – 2025-03-31798000 USD20260506Open filing evidence
2024-07-01 – 2024-09-30759000 USD20251104Open filing evidence
2024-01-01 – 2024-09-302195000 USD20251104Open filing evidence
2024-04-01 – 2024-06-30755000 USD20250806Open filing evidence
2024-01-01 – 2024-06-301436000 USD20250806Open filing evidence
2024-01-01 – 2024-03-31681000 USD20250507Open filing evidence
2023-07-01 – 2023-09-30654000 USD20241031Open filing evidence
2023-01-01 – 2023-09-302122000 USD20241031Open filing evidence

Analytical Reference Standards And Services Segment · Services And Other

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdcx:ServicesAndOtherMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-09-3012000 USD20261104Open filing evidence
2025-07-01 – 2025-09-3015000 USD20261104Open filing evidence
2025-01-01 – 2025-09-3055000 USD20261104Open filing evidence

Analytical Reference Standards And Services Segment · TRUNIAGEN Consumer Product

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdcx:TRUNIAGENConsumerProductMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-03-310 USD20260506Open filing evidence
2025-07-01 – 2025-09-300 USD20261104Open filing evidence
2025-01-01 – 2025-09-300 USD20261104Open filing evidence
2025-04-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-03-310 USD20260506Open filing evidence
2024-07-01 – 2024-09-300 USD20251104Open filing evidence
2024-01-01 – 2024-09-300 USD20251104Open filing evidence
2024-04-01 – 2024-06-300 USD20250806Open filing evidence
2024-01-01 – 2024-06-300 USD20250806Open filing evidence
2024-01-01 – 2024-03-310 USD20250507Open filing evidence
2023-07-01 – 2023-09-300 USD20241031Open filing evidence
2023-01-01 – 2023-09-300 USD20241031Open filing evidence

Consumer Products Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-3023320000 USD20261104Open filing evidence
2026-01-01 – 2026-09-3069895000 USD20261104Open filing evidence
2026-04-01 – 2026-06-3024162000 USD20260804Open filing evidence
2026-01-01 – 2026-06-3046575000 USD20260804Open filing evidence
2026-01-01 – 2026-03-3122413000 USD20260506Open filing evidence
2025-07-01 – 2025-09-3026017000 USD20261104Open filing evidence
2025-01-01 – 2025-09-3070217000 USD20261104Open filing evidence
2025-04-01 – 2025-06-3022699000 USD20260804Open filing evidence
2025-01-01 – 2025-06-3044200000 USD20260804Open filing evidence
2025-01-01 – 2025-03-3121501000 USD20260506Open filing evidence
2024-07-01 – 2024-09-3018123000 USD20251104Open filing evidence
2024-01-01 – 2024-09-3054121000 USD20251104Open filing evidence
2024-04-01 – 2024-06-3018647000 USD20250806Open filing evidence
2024-01-01 – 2024-06-3035998000 USD20250806Open filing evidence
2024-01-01 – 2024-03-3117351000 USD20250507Open filing evidence
2023-07-01 – 2023-09-3017400000 USD20241031Open filing evidence
2023-01-01 – 2023-09-3051924000 USD20241031Open filing evidence

Consumer Products Segment · Operating Segments

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-3023320000 USD20261104Open filing evidence
2026-01-01 – 2026-09-3069895000 USD20261104Open filing evidence
2025-07-01 – 2025-09-3026017000 USD20261104Open filing evidence
2025-01-01 – 2025-09-3070217000 USD20261104Open filing evidence
2023-07-01 – 2023-09-3017400000 USD20231108Open filing evidence
2023-01-01 – 2023-09-3051924000 USD20231108Open filing evidence

Consumer Products Segment · Consulting And Other

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:ConsultingAndOtherMember
PeriodValueUnitFiledEvidence
2026-01-01 – 2026-03-310 USD20260506Open filing evidence
2025-07-01 – 2025-09-300 USD20251104Open filing evidence
2025-01-01 – 2025-09-300 USD20251104Open filing evidence
2025-04-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-03-310 USD20260506Open filing evidence
2024-07-01 – 2024-09-300 USD20251104Open filing evidence
2024-01-01 – 2024-09-300 USD20251104Open filing evidence
2024-04-01 – 2024-06-300 USD20250806Open filing evidence
2024-01-01 – 2024-06-300 USD20250806Open filing evidence
2024-01-01 – 2024-03-310 USD20250507Open filing evidence
2023-07-01 – 2023-09-300 USD20241031Open filing evidence
2023-01-01 – 2023-09-300 USD20241031Open filing evidence

Consumer Products Segment · Food Grade NIAGEN

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:FoodGradeNIAGENMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-03-310 USD20260506Open filing evidence
2025-07-01 – 2025-09-300 USD20261104Open filing evidence
2025-01-01 – 2025-09-300 USD20261104Open filing evidence
2025-04-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-03-310 USD20260506Open filing evidence
2024-07-01 – 2024-09-300 USD20251104Open filing evidence
2024-01-01 – 2024-09-300 USD20251104Open filing evidence
2024-04-01 – 2024-06-300 USD20250806Open filing evidence
2024-01-01 – 2024-06-300 USD20250806Open filing evidence
2024-01-01 – 2024-03-310 USD20250507Open filing evidence
2023-07-01 – 2023-09-300 USD20241031Open filing evidence
2023-01-01 – 2023-09-300 USD20241031Open filing evidence

Consumer Products Segment · NIAGEN Ingredient

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:NIAGENIngredientMember
PeriodValueUnitFiledEvidence
2024-04-01 – 2024-06-300 USD20240807Open filing evidence
2024-01-01 – 2024-06-300 USD20240807Open filing evidence
2023-07-01 – 2023-09-300 USD20231108Open filing evidence
2023-01-01 – 2023-09-300 USD20231108Open filing evidence

Consumer Products Segment · NIAGEN Related

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:NIAGENRelatedMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-3023320000 USD20261104Open filing evidence
2026-01-01 – 2026-09-3069895000 USD20261104Open filing evidence
2026-01-01 – 2026-03-3122413000 USD20260506Open filing evidence
2025-07-01 – 2025-09-3026017000 USD20261104Open filing evidence
2025-01-01 – 2025-09-3070217000 USD20261104Open filing evidence
2025-04-01 – 2025-06-3022699000 USD20250806Open filing evidence
2025-01-01 – 2025-06-3044200000 USD20250806Open filing evidence
2025-01-01 – 2025-03-3121501000 USD20260506Open filing evidence
2024-07-01 – 2024-09-3018123000 USD20251104Open filing evidence
2024-01-01 – 2024-09-3054121000 USD20251104Open filing evidence
2024-04-01 – 2024-06-3018647000 USD20250806Open filing evidence
2024-01-01 – 2024-06-3035998000 USD20250806Open filing evidence
2024-01-01 – 2024-03-3117351000 USD20250507Open filing evidence
2023-07-01 – 2023-09-3017400000 USD20241031Open filing evidence
2023-01-01 – 2023-09-3051924000 USD20241031Open filing evidence

Consumer Products Segment · Other Goods And Services

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:OtherGoodsAndServicesMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-03-310 USD20260506Open filing evidence
2025-07-01 – 2025-09-300 USD20261104Open filing evidence
2025-01-01 – 2025-09-300 USD20261104Open filing evidence
2025-04-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-03-310 USD20260506Open filing evidence
2024-07-01 – 2024-09-300 USD20251104Open filing evidence
2024-01-01 – 2024-09-300 USD20251104Open filing evidence
2024-04-01 – 2024-06-300 USD20250806Open filing evidence
2024-01-01 – 2024-06-300 USD20250806Open filing evidence
2024-01-01 – 2024-03-310 USD20250507Open filing evidence
2023-07-01 – 2023-09-300 USD20241031Open filing evidence
2023-01-01 – 2023-09-300 USD20241031Open filing evidence

Consumer Products Segment · Other Ingredients

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:OtherIngredientsMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-03-310 USD20260506Open filing evidence
2025-07-01 – 2025-09-300 USD20261104Open filing evidence
2025-01-01 – 2025-09-300 USD20261104Open filing evidence
2025-04-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-03-310 USD20260506Open filing evidence
2024-07-01 – 2024-09-300 USD20251104Open filing evidence
2024-01-01 – 2024-09-300 USD20251104Open filing evidence
2024-04-01 – 2024-06-300 USD20250806Open filing evidence
2024-01-01 – 2024-06-300 USD20250806Open filing evidence
2024-01-01 – 2024-03-310 USD20250507Open filing evidence
2023-07-01 – 2023-09-300 USD20241031Open filing evidence
2023-01-01 – 2023-09-300 USD20241031Open filing evidence

Consumer Products Segment · Pharmaceutical Grade NIAGEN

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:PharmaceuticalGradeNIAGENMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-03-310 USD20260506Open filing evidence
2025-07-01 – 2025-09-300 USD20261104Open filing evidence
2025-01-01 – 2025-09-300 USD20261104Open filing evidence
2025-04-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-03-310 USD20260506Open filing evidence
2024-07-01 – 2024-09-300 USD20251104Open filing evidence
2024-01-01 – 2024-09-300 USD20251104Open filing evidence
2024-01-01 – 2024-03-310 USD20250507Open filing evidence
2023-07-01 – 2023-09-300 USD20241031Open filing evidence
2023-01-01 – 2023-09-300 USD20241031Open filing evidence

Consumer Products Segment · Reference Standards

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:ReferenceStandardsMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-03-310 USD20260506Open filing evidence
2025-07-01 – 2025-09-300 USD20261104Open filing evidence
2025-01-01 – 2025-09-300 USD20261104Open filing evidence
2025-04-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-03-310 USD20260506Open filing evidence
2024-07-01 – 2024-09-300 USD20251104Open filing evidence
2024-01-01 – 2024-09-300 USD20251104Open filing evidence
2024-04-01 – 2024-06-300 USD20250806Open filing evidence
2024-01-01 – 2024-06-300 USD20250806Open filing evidence
2024-01-01 – 2024-03-310 USD20250507Open filing evidence
2023-07-01 – 2023-09-300 USD20241031Open filing evidence
2023-01-01 – 2023-09-300 USD20241031Open filing evidence

Consumer Products Segment · Services And Other

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:ServicesAndOtherMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-09-300 USD20261104Open filing evidence
2025-07-01 – 2025-09-300 USD20261104Open filing evidence
2025-01-01 – 2025-09-300 USD20261104Open filing evidence

Consumer Products Segment · TRUNIAGEN Consumer Product

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:TRUNIAGENConsumerProductMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-3023320000 USD20261104Open filing evidence
2026-01-01 – 2026-09-3069895000 USD20261104Open filing evidence
2026-01-01 – 2026-03-3122413000 USD20260506Open filing evidence
2025-07-01 – 2025-09-3026017000 USD20261104Open filing evidence
2025-01-01 – 2025-09-3070217000 USD20261104Open filing evidence
2025-04-01 – 2025-06-3022699000 USD20250806Open filing evidence
2025-01-01 – 2025-06-3044200000 USD20250806Open filing evidence
2025-01-01 – 2025-03-3121501000 USD20260506Open filing evidence
2024-07-01 – 2024-09-3018123000 USD20251104Open filing evidence
2024-01-01 – 2024-09-3054121000 USD20251104Open filing evidence
2024-04-01 – 2024-06-3018647000 USD20250806Open filing evidence
2024-01-01 – 2024-06-3035998000 USD20250806Open filing evidence
2024-01-01 – 2024-03-3117351000 USD20250507Open filing evidence
2023-07-01 – 2023-09-3017400000 USD20241031Open filing evidence
2023-01-01 – 2023-09-3051924000 USD20241031Open filing evidence

Corporate And Reconciling Items

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-3070000 USD20261104Open filing evidence
2026-01-01 – 2026-09-30380000 USD20261104Open filing evidence
2026-04-01 – 2026-06-30236000 USD20260804Open filing evidence
2026-01-01 – 2026-06-30310000 USD20260804Open filing evidence
2026-01-01 – 2026-03-3174000 USD20260506Open filing evidence

Corporate And Reconciling Items · Consulting And Other

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember;us-gaap:SubsegmentsAxis=cdcx:ConsultingAndOtherMember
PeriodValueUnitFiledEvidence
2026-01-01 – 2026-03-3174000 USD20260506Open filing evidence

Corporate And Reconciling Items · Food Grade NIAGEN

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember;us-gaap:SubsegmentsAxis=cdcx:FoodGradeNIAGENMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-03-310 USD20260506Open filing evidence

Corporate And Reconciling Items · NIAGEN Related

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember;us-gaap:SubsegmentsAxis=cdcx:NIAGENRelatedMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-03-310 USD20260506Open filing evidence

Corporate And Reconciling Items · Other Goods And Services

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember;us-gaap:SubsegmentsAxis=cdcx:OtherGoodsAndServicesMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-3070000 USD20261104Open filing evidence
2026-01-01 – 2026-09-30380000 USD20261104Open filing evidence
2026-01-01 – 2026-03-3174000 USD20260506Open filing evidence

Corporate And Reconciling Items · Other Ingredients

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember;us-gaap:SubsegmentsAxis=cdcx:OtherIngredientsMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-03-310 USD20260506Open filing evidence

Corporate And Reconciling Items · Pharmaceutical Grade NIAGEN

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember;us-gaap:SubsegmentsAxis=cdcx:PharmaceuticalGradeNIAGENMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-03-310 USD20260506Open filing evidence

Corporate And Reconciling Items · Reference Standards

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember;us-gaap:SubsegmentsAxis=cdcx:ReferenceStandardsMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-03-310 USD20260506Open filing evidence

Corporate And Reconciling Items · Services And Other

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember;us-gaap:SubsegmentsAxis=cdcx:ServicesAndOtherMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-3070000 USD20261104Open filing evidence
2026-01-01 – 2026-09-30380000 USD20261104Open filing evidence

Corporate And Reconciling Items · TRUNIAGEN Consumer Product

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember;us-gaap:SubsegmentsAxis=cdcx:TRUNIAGENConsumerProductMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-03-310 USD20260506Open filing evidence

Ingredients Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-303802000 USD20261104Open filing evidence
2026-01-01 – 2026-09-3017753000 USD20261104Open filing evidence
2026-04-01 – 2026-06-305387000 USD20260804Open filing evidence
2026-01-01 – 2026-06-3013951000 USD20260804Open filing evidence
2026-01-01 – 2026-03-318564000 USD20260506Open filing evidence
2025-07-01 – 2025-09-307197000 USD20261104Open filing evidence
2025-01-01 – 2025-09-3022985000 USD20261104Open filing evidence
2025-04-01 – 2025-06-307619000 USD20260804Open filing evidence
2025-01-01 – 2025-06-3015788000 USD20260804Open filing evidence
2025-01-01 – 2025-03-318169000 USD20260506Open filing evidence
2024-07-01 – 2024-09-306673000 USD20251104Open filing evidence
2024-01-01 – 2024-09-3014062000 USD20251104Open filing evidence
2024-04-01 – 2024-06-303301000 USD20250806Open filing evidence
2024-01-01 – 2024-06-307389000 USD20250806Open filing evidence
2024-01-01 – 2024-03-314088000 USD20250507Open filing evidence
2023-07-01 – 2023-09-301424000 USD20241031Open filing evidence
2023-01-01 – 2023-09-308252000 USD20241031Open filing evidence

Ingredients Segment · Operating Segments

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-303802000 USD20261104Open filing evidence
2026-01-01 – 2026-09-3017753000 USD20261104Open filing evidence
2025-07-01 – 2025-09-307197000 USD20261104Open filing evidence
2025-01-01 – 2025-09-3022985000 USD20261104Open filing evidence
2024-04-01 – 2024-06-303301000 USD20240807Open filing evidence
2024-01-01 – 2024-06-307389000 USD20240807Open filing evidence
2023-07-01 – 2023-09-301424000 USD20231108Open filing evidence
2023-01-01 – 2023-09-308252000 USD20231108Open filing evidence

Ingredients Segment · Consulting And Other

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:ConsultingAndOtherMember
PeriodValueUnitFiledEvidence
2026-01-01 – 2026-03-310 USD20260506Open filing evidence
2025-07-01 – 2025-09-300 USD20251104Open filing evidence
2025-01-01 – 2025-09-300 USD20251104Open filing evidence
2025-04-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-03-310 USD20260506Open filing evidence
2024-07-01 – 2024-09-300 USD20251104Open filing evidence
2024-01-01 – 2024-09-300 USD20251104Open filing evidence
2024-04-01 – 2024-06-300 USD20250806Open filing evidence
2024-01-01 – 2024-06-300 USD20250806Open filing evidence
2024-01-01 – 2024-03-310 USD20250507Open filing evidence
2023-07-01 – 2023-09-300 USD20241031Open filing evidence
2023-01-01 – 2023-09-300 USD20241031Open filing evidence

Ingredients Segment · Food Grade NIAGEN

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:FoodGradeNIAGENMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-303372000 USD20261104Open filing evidence
2026-01-01 – 2026-09-3015609000 USD20261104Open filing evidence
2026-01-01 – 2026-03-317309000 USD20260506Open filing evidence
2025-07-01 – 2025-09-306405000 USD20261104Open filing evidence
2025-01-01 – 2025-09-3019373000 USD20261104Open filing evidence
2025-04-01 – 2025-06-305994000 USD20250806Open filing evidence
2025-01-01 – 2025-06-3012968000 USD20250806Open filing evidence
2025-01-01 – 2025-03-316974000 USD20260506Open filing evidence
2024-07-01 – 2024-09-305760000 USD20251104Open filing evidence
2024-01-01 – 2024-09-3012992000 USD20251104Open filing evidence
2024-04-01 – 2024-06-303144000 USD20250806Open filing evidence
2024-01-01 – 2024-06-307232000 USD20250806Open filing evidence
2024-01-01 – 2024-03-314088000 USD20250507Open filing evidence
2023-07-01 – 2023-09-301424000 USD20241031Open filing evidence
2023-01-01 – 2023-09-307822000 USD20241031Open filing evidence

Ingredients Segment · NIAGEN Ingredient

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:NIAGENIngredientMember
PeriodValueUnitFiledEvidence
2024-04-01 – 2024-06-303144000 USD20240807Open filing evidence
2024-01-01 – 2024-06-307232000 USD20240807Open filing evidence
2023-07-01 – 2023-09-301424000 USD20231108Open filing evidence
2023-01-01 – 2023-09-307822000 USD20231108Open filing evidence

Ingredients Segment · NIAGEN Related

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:NIAGENRelatedMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-303797000 USD20261104Open filing evidence
2026-01-01 – 2026-09-3017309000 USD20261104Open filing evidence
2026-01-01 – 2026-03-318159000 USD20260506Open filing evidence
2025-07-01 – 2025-09-306915000 USD20261104Open filing evidence
2025-01-01 – 2025-09-3022273000 USD20261104Open filing evidence
2025-04-01 – 2025-06-307384000 USD20250806Open filing evidence
2025-01-01 – 2025-06-3015358000 USD20250806Open filing evidence
2025-01-01 – 2025-03-317974000 USD20260506Open filing evidence
2024-07-01 – 2024-09-306660000 USD20251104Open filing evidence
2024-01-01 – 2024-09-3013892000 USD20251104Open filing evidence
2024-04-01 – 2024-06-303144000 USD20250806Open filing evidence
2024-01-01 – 2024-06-307232000 USD20250806Open filing evidence
2024-01-01 – 2024-03-314088000 USD20250507Open filing evidence
2023-07-01 – 2023-09-301424000 USD20241031Open filing evidence
2023-01-01 – 2023-09-307822000 USD20241031Open filing evidence

Ingredients Segment · Other Goods And Services

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:OtherGoodsAndServicesMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-305000 USD20261104Open filing evidence
2026-01-01 – 2026-09-30444000 USD20261104Open filing evidence
2026-01-01 – 2026-03-31405000 USD20260506Open filing evidence
2025-07-01 – 2025-09-30282000 USD20261104Open filing evidence
2025-01-01 – 2025-09-30712000 USD20261104Open filing evidence
2025-04-01 – 2025-06-30235000 USD20250806Open filing evidence
2025-01-01 – 2025-06-30430000 USD20250806Open filing evidence
2025-01-01 – 2025-03-31195000 USD20260506Open filing evidence
2024-07-01 – 2024-09-3013000 USD20251104Open filing evidence
2024-01-01 – 2024-09-30170000 USD20251104Open filing evidence
2024-04-01 – 2024-06-30157000 USD20250806Open filing evidence
2024-01-01 – 2024-06-30157000 USD20250806Open filing evidence
2024-01-01 – 2024-03-310 USD20250507Open filing evidence
2023-07-01 – 2023-09-300 USD20241031Open filing evidence
2023-01-01 – 2023-09-30430000 USD20241031Open filing evidence

Ingredients Segment · Other Ingredients

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:OtherIngredientsMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-09-30430000 USD20261104Open filing evidence
2026-01-01 – 2026-03-31405000 USD20260506Open filing evidence
2025-07-01 – 2025-09-30282000 USD20261104Open filing evidence
2025-01-01 – 2025-09-30712000 USD20261104Open filing evidence
2025-04-01 – 2025-06-30235000 USD20250806Open filing evidence
2025-01-01 – 2025-06-30430000 USD20250806Open filing evidence
2025-01-01 – 2025-03-31195000 USD20260506Open filing evidence
2024-07-01 – 2024-09-3013000 USD20251104Open filing evidence
2024-01-01 – 2024-09-30170000 USD20251104Open filing evidence
2024-04-01 – 2024-06-30157000 USD20250806Open filing evidence
2024-01-01 – 2024-06-30157000 USD20250806Open filing evidence
2024-01-01 – 2024-03-310 USD20250507Open filing evidence
2023-07-01 – 2023-09-300 USD20241031Open filing evidence
2023-01-01 – 2023-09-30430000 USD20241031Open filing evidence

Ingredients Segment · Pharmaceutical Grade NIAGEN

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:PharmaceuticalGradeNIAGENMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-30425000 USD20261104Open filing evidence
2026-01-01 – 2026-09-301700000 USD20261104Open filing evidence
2026-01-01 – 2026-03-31850000 USD20260506Open filing evidence
2025-07-01 – 2025-09-30510000 USD20261104Open filing evidence
2025-01-01 – 2025-09-302900000 USD20261104Open filing evidence
2025-04-01 – 2025-06-301390000 USD20250806Open filing evidence
2025-01-01 – 2025-06-302390000 USD20250806Open filing evidence
2025-01-01 – 2025-03-311000000 USD20260506Open filing evidence
2024-07-01 – 2024-09-30900000 USD20251104Open filing evidence
2024-01-01 – 2024-09-30900000 USD20251104Open filing evidence
2024-01-01 – 2024-03-310 USD20250507Open filing evidence
2023-07-01 – 2023-09-300 USD20241031Open filing evidence
2023-01-01 – 2023-09-300 USD20241031Open filing evidence

Ingredients Segment · Reference Standards

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:ReferenceStandardsMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-03-310 USD20260506Open filing evidence
2025-07-01 – 2025-09-300 USD20261104Open filing evidence
2025-01-01 – 2025-09-300 USD20261104Open filing evidence
2025-04-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-03-310 USD20260506Open filing evidence
2024-07-01 – 2024-09-300 USD20251104Open filing evidence
2024-01-01 – 2024-09-300 USD20251104Open filing evidence
2024-04-01 – 2024-06-300 USD20250806Open filing evidence
2024-01-01 – 2024-06-300 USD20250806Open filing evidence
2024-01-01 – 2024-03-310 USD20250507Open filing evidence
2023-07-01 – 2023-09-300 USD20241031Open filing evidence
2023-01-01 – 2023-09-300 USD20241031Open filing evidence

Ingredients Segment · Services And Other

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:ServicesAndOtherMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-305000 USD20261104Open filing evidence
2026-01-01 – 2026-09-3014000 USD20261104Open filing evidence
2025-07-01 – 2025-09-300 USD20261104Open filing evidence
2025-01-01 – 2025-09-300 USD20261104Open filing evidence

Ingredients Segment · TRUNIAGEN Consumer Product

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdcx:TRUNIAGENConsumerProductMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-03-310 USD20260506Open filing evidence
2025-07-01 – 2025-09-300 USD20261104Open filing evidence
2025-01-01 – 2025-09-300 USD20261104Open filing evidence
2025-04-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-06-300 USD20250806Open filing evidence
2025-01-01 – 2025-03-310 USD20260506Open filing evidence
2024-07-01 – 2024-09-300 USD20251104Open filing evidence
2024-01-01 – 2024-09-300 USD20251104Open filing evidence
2024-04-01 – 2024-06-300 USD20250806Open filing evidence
2024-01-01 – 2024-06-300 USD20250806Open filing evidence
2024-01-01 – 2024-03-310 USD20250507Open filing evidence
2023-07-01 – 2023-09-300 USD20241031Open filing evidence
2023-01-01 – 2023-09-300 USD20241031Open filing evidence

Pharmaceuticals Segment · Operating Segments

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdcx:PharmaceuticalsSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-300 USD20261104Open filing evidence
2026-01-01 – 2026-09-300 USD20261104Open filing evidence
2025-07-01 – 2025-09-300 USD20261104Open filing evidence
2025-01-01 – 2025-09-300 USD20261104Open filing evidence

Analytical Reference Standards And Services Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-313076000 USD20260304Open filing evidence
2024-01-01 – 2024-12-313011000 USD20260304Open filing evidence
2023-01-01 – 2023-12-312905000 USD20250304Open filing evidence

Analytical Reference Standards And Services Segment · Consulting And Other

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdxc:ConsultingAndOtherMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-3173000 USD20260304Open filing evidence
2024-01-01 – 2024-12-31120000 USD20260304Open filing evidence
2023-01-01 – 2023-12-31101000 USD20250304Open filing evidence

Analytical Reference Standards And Services Segment · NIAGEN Ingredient

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdxc:NIAGENIngredientMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-310 USD20260304Open filing evidence
2024-01-01 – 2024-12-310 USD20260304Open filing evidence
2023-01-01 – 2023-12-310 USD20250304Open filing evidence

Analytical Reference Standards And Services Segment · NIAGEN Related

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdxc:NIAGENRelatedMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-310 USD20260304Open filing evidence
2024-01-01 – 2024-12-310 USD20260304Open filing evidence
2023-01-01 – 2023-12-310 USD20250304Open filing evidence

Analytical Reference Standards And Services Segment · Other Goods And Services

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdxc:OtherGoodsAndServicesMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-313076000 USD20260304Open filing evidence
2024-01-01 – 2024-12-313011000 USD20260304Open filing evidence
2023-01-01 – 2023-12-312905000 USD20250304Open filing evidence

Analytical Reference Standards And Services Segment · Other Ingredients

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdxc:OtherIngredientsMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-310 USD20260304Open filing evidence
2024-01-01 – 2024-12-310 USD20260304Open filing evidence
2023-01-01 – 2023-12-310 USD20250304Open filing evidence

Analytical Reference Standards And Services Segment · Pharmaceutical Grade Niagen

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdxc:PharmaceuticalGradeNiagenMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-310 USD20260304Open filing evidence
2024-01-01 – 2024-12-310 USD20260304Open filing evidence
2023-01-01 – 2023-12-310 USD20250304Open filing evidence

Analytical Reference Standards And Services Segment · Reference Standards

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdxc:ReferenceStandardsMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-313003000 USD20260304Open filing evidence
2024-01-01 – 2024-12-312891000 USD20260304Open filing evidence
2023-01-01 – 2023-12-312804000 USD20250304Open filing evidence

Analytical Reference Standards And Services Segment · TRUNIAGEN Consumer Product

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember;us-gaap:SubsegmentsAxis=cdxc:TRUNIAGENConsumerProductMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-310 USD20260304Open filing evidence
2024-01-01 – 2024-12-310 USD20260304Open filing evidence
2023-01-01 – 2023-12-310 USD20250304Open filing evidence

Consumer Products Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdxc:ConsumerProductsSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-3197672000 USD20260304Open filing evidence
2024-01-01 – 2024-12-3176772000 USD20260304Open filing evidence
2023-01-01 – 2023-12-3169528000 USD20250304Open filing evidence

Consumer Products Segment · Consulting And Other

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdxc:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:ConsultingAndOtherMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-310 USD20260304Open filing evidence
2024-01-01 – 2024-12-310 USD20260304Open filing evidence
2023-01-01 – 2023-12-310 USD20250304Open filing evidence

Consumer Products Segment · NIAGEN Ingredient

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdxc:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:NIAGENIngredientMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-310 USD20260304Open filing evidence
2024-01-01 – 2024-12-310 USD20260304Open filing evidence
2023-01-01 – 2023-12-310 USD20250304Open filing evidence

Consumer Products Segment · NIAGEN Related

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdxc:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:NIAGENRelatedMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-3197672000 USD20260304Open filing evidence
2024-01-01 – 2024-12-3176772000 USD20260304Open filing evidence
2023-01-01 – 2023-12-3169528000 USD20250304Open filing evidence

Consumer Products Segment · Other Goods And Services

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdxc:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:OtherGoodsAndServicesMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-310 USD20260304Open filing evidence
2024-01-01 – 2024-12-310 USD20260304Open filing evidence
2023-01-01 – 2023-12-310 USD20250304Open filing evidence

Consumer Products Segment · Other Ingredients

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdxc:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:OtherIngredientsMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-310 USD20260304Open filing evidence
2024-01-01 – 2024-12-310 USD20260304Open filing evidence
2023-01-01 – 2023-12-310 USD20250304Open filing evidence

Consumer Products Segment · Pharmaceutical Grade Niagen

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdxc:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:PharmaceuticalGradeNiagenMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-310 USD20260304Open filing evidence
2024-01-01 – 2024-12-310 USD20260304Open filing evidence
2023-01-01 – 2023-12-310 USD20250304Open filing evidence

Consumer Products Segment · Reference Standards

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdxc:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:ReferenceStandardsMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-310 USD20260304Open filing evidence
2024-01-01 – 2024-12-310 USD20260304Open filing evidence
2023-01-01 – 2023-12-310 USD20250304Open filing evidence

Consumer Products Segment · TRUNIAGEN Consumer Product

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdxc:ConsumerProductsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:TRUNIAGENConsumerProductMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-3197672000 USD20260304Open filing evidence
2024-01-01 – 2024-12-3176772000 USD20260304Open filing evidence
2023-01-01 – 2023-12-3169528000 USD20250304Open filing evidence

Ingredients Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdxc:IngredientsSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-3128675000 USD20260304Open filing evidence
2024-01-01 – 2024-12-3119814000 USD20260304Open filing evidence
2023-01-01 – 2023-12-3111137000 USD20250304Open filing evidence

Ingredients Segment · Consulting And Other

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdxc:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:ConsultingAndOtherMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-310 USD20260304Open filing evidence
2024-01-01 – 2024-12-310 USD20260304Open filing evidence
2023-01-01 – 2023-12-310 USD20250304Open filing evidence

Ingredients Segment · NIAGEN Ingredient

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdxc:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:NIAGENIngredientMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-3124110000 USD20260304Open filing evidence
2024-01-01 – 2024-12-3117540000 USD20260304Open filing evidence
2023-01-01 – 2023-12-3110550000 USD20250304Open filing evidence

Ingredients Segment · NIAGEN Related

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdxc:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:NIAGENRelatedMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-3127894000 USD20260304Open filing evidence
2024-01-01 – 2024-12-3119240000 USD20260304Open filing evidence
2023-01-01 – 2023-12-3110550000 USD20250304Open filing evidence

Ingredients Segment · Other Goods And Services

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdxc:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:OtherGoodsAndServicesMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-31781000 USD20260304Open filing evidence
2024-01-01 – 2024-12-31574000 USD20260304Open filing evidence
2023-01-01 – 2023-12-31587000 USD20250304Open filing evidence

Ingredients Segment · Other Ingredients

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdxc:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:OtherIngredientsMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-31781000 USD20260304Open filing evidence
2024-01-01 – 2024-12-31574000 USD20260304Open filing evidence
2023-01-01 – 2023-12-31587000 USD20250304Open filing evidence

Ingredients Segment · Pharmaceutical Grade Niagen

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdxc:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:PharmaceuticalGradeNiagenMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-313784000 USD20260304Open filing evidence
2024-01-01 – 2024-12-311700000 USD20260304Open filing evidence
2023-01-01 – 2023-12-310 USD20250304Open filing evidence

Ingredients Segment · Reference Standards

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdxc:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:ReferenceStandardsMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-310 USD20260304Open filing evidence
2024-01-01 – 2024-12-310 USD20260304Open filing evidence
2023-01-01 – 2023-12-310 USD20250304Open filing evidence

Ingredients Segment · TRUNIAGEN Consumer Product

Statement Business Segments · Subsegments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=cdxc:IngredientsSegmentMember;us-gaap:SubsegmentsAxis=cdxc:TRUNIAGENConsumerProductMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-310 USD20260304Open filing evidence
2024-01-01 – 2024-12-310 USD20260304Open filing evidence
2023-01-01 – 2023-12-310 USD20250304Open filing evidence

Food Grade NIAGEN · Analytical Reference Standards And Services Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:FoodGradeNIAGENMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-300 USD20260804Open filing evidence
2026-01-01 – 2026-06-300 USD20260804Open filing evidence
2025-04-01 – 2025-06-300 USD20260804Open filing evidence
2025-01-01 – 2025-06-300 USD20260804Open filing evidence

Food Grade NIAGEN · Consumer Products Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:FoodGradeNIAGENMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-300 USD20260804Open filing evidence
2026-01-01 – 2026-06-300 USD20260804Open filing evidence
2025-04-01 – 2025-06-300 USD20260804Open filing evidence
2025-01-01 – 2025-06-300 USD20260804Open filing evidence

Food Grade NIAGEN · Corporate And Reconciling Items

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:FoodGradeNIAGENMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-300 USD20260804Open filing evidence
2026-01-01 – 2026-06-300 USD20260804Open filing evidence

Food Grade NIAGEN · Ingredients Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:FoodGradeNIAGENMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-304928000 USD20260804Open filing evidence
2026-01-01 – 2026-06-3012237000 USD20260804Open filing evidence
2025-04-01 – 2025-06-305994000 USD20260804Open filing evidence
2025-01-01 – 2025-06-3012968000 USD20260804Open filing evidence

NIAGEN Ingredient · Analytical Reference Standards And Services Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:NIAGENIngredientMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember
PeriodValueUnitFiledEvidence
2024-01-01 – 2024-03-310 USD20240508Open filing evidence
2023-07-01 – 2023-09-300 USD20231108Open filing evidence
2023-01-01 – 2023-09-300 USD20231108Open filing evidence

NIAGEN Ingredient · Consumer Products Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:NIAGENIngredientMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember
PeriodValueUnitFiledEvidence
2024-01-01 – 2024-03-310 USD20240508Open filing evidence

NIAGEN Ingredient · Ingredients Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:NIAGENIngredientMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember
PeriodValueUnitFiledEvidence
2024-01-01 – 2024-03-314088000 USD20240508Open filing evidence

NIAGEN Related · Analytical Reference Standards And Services Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:NIAGENRelatedMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-300 USD20260804Open filing evidence
2026-01-01 – 2026-06-300 USD20260804Open filing evidence
2025-04-01 – 2025-06-300 USD20260804Open filing evidence
2025-01-01 – 2025-06-300 USD20260804Open filing evidence
2024-04-01 – 2024-06-300 USD20240807Open filing evidence
2024-01-01 – 2024-06-300 USD20240807Open filing evidence

NIAGEN Related · Consumer Products Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:NIAGENRelatedMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-3024162000 USD20260804Open filing evidence
2026-01-01 – 2026-06-3046575000 USD20260804Open filing evidence
2025-04-01 – 2025-06-3022699000 USD20260804Open filing evidence
2025-01-01 – 2025-06-3044200000 USD20260804Open filing evidence
2024-04-01 – 2024-06-3018647000 USD20240807Open filing evidence
2024-01-01 – 2024-06-3035998000 USD20240807Open filing evidence
2024-01-01 – 2024-03-3117351000 USD20240508Open filing evidence

NIAGEN Related · Corporate And Reconciling Items

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:NIAGENRelatedMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-300 USD20260804Open filing evidence
2026-01-01 – 2026-06-300 USD20260804Open filing evidence

NIAGEN Related · Ingredients Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:NIAGENRelatedMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-305353000 USD20260804Open filing evidence
2026-01-01 – 2026-06-3013512000 USD20260804Open filing evidence
2025-04-01 – 2025-06-307384000 USD20260804Open filing evidence
2025-01-01 – 2025-06-3015358000 USD20260804Open filing evidence
2024-04-01 – 2024-06-303144000 USD20240807Open filing evidence
2024-01-01 – 2024-06-307232000 USD20240807Open filing evidence

Other Goods And Services · Analytical Reference Standards And Services Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:OtherGoodsAndServicesMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-300 USD20260804Open filing evidence
2026-01-01 – 2026-06-30423000 USD20260804Open filing evidence
2025-04-01 – 2025-06-30799000 USD20260804Open filing evidence
2025-01-01 – 2025-06-301610000 USD20260804Open filing evidence

Other Goods And Services · Consumer Products Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:OtherGoodsAndServicesMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-300 USD20260804Open filing evidence
2026-01-01 – 2026-06-300 USD20260804Open filing evidence
2025-04-01 – 2025-06-300 USD20260804Open filing evidence
2025-01-01 – 2025-06-300 USD20260804Open filing evidence
2024-01-01 – 2024-03-310 USD20240508Open filing evidence

Other Goods And Services · Corporate And Reconciling Items

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:OtherGoodsAndServicesMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-30236000 USD20260804Open filing evidence
2026-01-01 – 2026-06-30310000 USD20260804Open filing evidence

Other Goods And Services · Ingredients Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:OtherGoodsAndServicesMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-3034000 USD20260804Open filing evidence
2026-01-01 – 2026-06-30439000 USD20260804Open filing evidence
2025-04-01 – 2025-06-30235000 USD20260804Open filing evidence
2025-01-01 – 2025-06-30430000 USD20260804Open filing evidence

Other Ingredients · Analytical Reference Standards And Services Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:OtherIngredientsMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-300 USD20260804Open filing evidence
2026-01-01 – 2026-06-300 USD20260804Open filing evidence
2025-04-01 – 2025-06-300 USD20260804Open filing evidence
2025-01-01 – 2025-06-300 USD20260804Open filing evidence
2024-01-01 – 2024-03-310 USD20240508Open filing evidence
2023-07-01 – 2023-09-300 USD20231108Open filing evidence
2023-01-01 – 2023-09-300 USD20231108Open filing evidence

Other Ingredients · Consumer Products Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:OtherIngredientsMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-300 USD20260804Open filing evidence
2026-01-01 – 2026-06-300 USD20260804Open filing evidence
2025-04-01 – 2025-06-300 USD20260804Open filing evidence
2025-01-01 – 2025-06-300 USD20260804Open filing evidence
2024-04-01 – 2024-06-300 USD20240807Open filing evidence
2024-01-01 – 2024-06-300 USD20240807Open filing evidence
2024-01-01 – 2024-03-310 USD20240508Open filing evidence

Other Ingredients · Corporate And Reconciling Items

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:OtherIngredientsMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-300 USD20260804Open filing evidence
2026-01-01 – 2026-06-300 USD20260804Open filing evidence

Other Ingredients · Ingredients Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:OtherIngredientsMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-3025000 USD20260804Open filing evidence
2026-01-01 – 2026-06-30430000 USD20260804Open filing evidence
2025-04-01 – 2025-06-30235000 USD20260804Open filing evidence
2025-01-01 – 2025-06-30430000 USD20260804Open filing evidence
2024-04-01 – 2024-06-30157000 USD20240807Open filing evidence
2024-01-01 – 2024-06-30157000 USD20240807Open filing evidence
2024-01-01 – 2024-03-310 USD20240508Open filing evidence

Pharmaceutical Grade NIAGEN · Analytical Reference Standards And Services Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:PharmaceuticalGradeNIAGENMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-300 USD20260804Open filing evidence
2026-01-01 – 2026-06-300 USD20260804Open filing evidence
2025-04-01 – 2025-06-300 USD20260804Open filing evidence
2025-01-01 – 2025-06-300 USD20260804Open filing evidence

Pharmaceutical Grade NIAGEN · Consumer Products Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:PharmaceuticalGradeNIAGENMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-300 USD20260804Open filing evidence
2026-01-01 – 2026-06-300 USD20260804Open filing evidence
2025-04-01 – 2025-06-300 USD20260804Open filing evidence
2025-01-01 – 2025-06-300 USD20260804Open filing evidence

Pharmaceutical Grade NIAGEN · Corporate And Reconciling Items

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:PharmaceuticalGradeNIAGENMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-300 USD20260804Open filing evidence
2026-01-01 – 2026-06-300 USD20260804Open filing evidence

Pharmaceutical Grade NIAGEN · Ingredients Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:PharmaceuticalGradeNIAGENMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-30425000 USD20260804Open filing evidence
2026-01-01 – 2026-06-301275000 USD20260804Open filing evidence
2025-04-01 – 2025-06-301390000 USD20260804Open filing evidence
2025-01-01 – 2025-06-302390000 USD20260804Open filing evidence

Reference Standards · Analytical Reference Standards And Services Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:ReferenceStandardsMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-300 USD20260804Open filing evidence
2026-01-01 – 2026-06-30411000 USD20260804Open filing evidence
2025-04-01 – 2025-06-30772000 USD20260804Open filing evidence
2025-01-01 – 2025-06-301570000 USD20260804Open filing evidence
2024-01-01 – 2024-03-31681000 USD20240508Open filing evidence

Reference Standards · Consumer Products Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:ReferenceStandardsMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-300 USD20260804Open filing evidence
2026-01-01 – 2026-06-300 USD20260804Open filing evidence
2025-04-01 – 2025-06-300 USD20260804Open filing evidence
2025-01-01 – 2025-06-300 USD20260804Open filing evidence
2024-04-01 – 2024-06-300 USD20240807Open filing evidence
2024-01-01 – 2024-06-300 USD20240807Open filing evidence
2024-01-01 – 2024-03-310 USD20240508Open filing evidence

Reference Standards · Corporate And Reconciling Items

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:ReferenceStandardsMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-300 USD20260804Open filing evidence
2026-01-01 – 2026-06-300 USD20260804Open filing evidence

Reference Standards · Ingredients Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:ReferenceStandardsMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-300 USD20260804Open filing evidence
2026-01-01 – 2026-06-300 USD20260804Open filing evidence
2025-04-01 – 2025-06-300 USD20260804Open filing evidence
2025-01-01 – 2025-06-300 USD20260804Open filing evidence
2024-01-01 – 2024-03-310 USD20240508Open filing evidence

Services And Other · Analytical Reference Standards And Services Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:ServicesAndOtherMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-300 USD20260804Open filing evidence
2026-01-01 – 2026-06-3012000 USD20260804Open filing evidence
2025-04-01 – 2025-06-3027000 USD20260804Open filing evidence
2025-01-01 – 2025-06-3040000 USD20260804Open filing evidence

Services And Other · Consumer Products Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:ServicesAndOtherMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-300 USD20260804Open filing evidence
2026-01-01 – 2026-06-300 USD20260804Open filing evidence
2025-04-01 – 2025-06-300 USD20260804Open filing evidence
2025-01-01 – 2025-06-300 USD20260804Open filing evidence

Services And Other · Corporate And Reconciling Items

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:ServicesAndOtherMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-30236000 USD20260804Open filing evidence
2026-01-01 – 2026-06-30310000 USD20260804Open filing evidence

Services And Other · Ingredients Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:ServicesAndOtherMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-309000 USD20260804Open filing evidence
2026-01-01 – 2026-06-309000 USD20260804Open filing evidence
2025-04-01 – 2025-06-300 USD20260804Open filing evidence
2025-01-01 – 2025-06-300 USD20260804Open filing evidence

TRUNIAGEN Consumer Product · Analytical Reference Standards And Services Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:TRUNIAGENConsumerProductMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:AnalyticalReferenceStandardsAndServicesSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-300 USD20260804Open filing evidence
2026-01-01 – 2026-06-300 USD20260804Open filing evidence
2025-04-01 – 2025-06-300 USD20260804Open filing evidence
2025-01-01 – 2025-06-300 USD20260804Open filing evidence

TRUNIAGEN Consumer Product · Consumer Products Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:TRUNIAGENConsumerProductMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:ConsumerProductsSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-3024162000 USD20260804Open filing evidence
2026-01-01 – 2026-06-3046575000 USD20260804Open filing evidence
2025-04-01 – 2025-06-3022699000 USD20260804Open filing evidence
2025-01-01 – 2025-06-3044200000 USD20260804Open filing evidence
2024-04-01 – 2024-06-3018647000 USD20240807Open filing evidence
2024-01-01 – 2024-06-3035998000 USD20240807Open filing evidence
2024-01-01 – 2024-03-3117351000 USD20240508Open filing evidence

TRUNIAGEN Consumer Product · Corporate And Reconciling Items

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:TRUNIAGENConsumerProductMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:CorporateAndReconcilingItemsMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-300 USD20260804Open filing evidence
2026-01-01 – 2026-06-300 USD20260804Open filing evidence

TRUNIAGEN Consumer Product · Ingredients Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdcx:TRUNIAGENConsumerProductMember;us-gaap:StatementBusinessSegmentsAxis=cdcx:IngredientsSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-300 USD20260804Open filing evidence
2026-01-01 – 2026-06-300 USD20260804Open filing evidence
2025-04-01 – 2025-06-300 USD20260804Open filing evidence
2025-01-01 – 2025-06-300 USD20260804Open filing evidence

Consulting And Other · Analytical Reference Standards And Services Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdxc:ConsultingAndOtherMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-31101000 USD20240306Open filing evidence

NIAGEN Ingredient · Analytical Reference Standards And Services Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdxc:NIAGENIngredientMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-310 USD20240306Open filing evidence

NIAGEN Ingredient · Consumer Products Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdxc:NIAGENIngredientMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:ConsumerProductsSegmentMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-310 USD20240306Open filing evidence

NIAGEN Ingredient · Ingredients Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdxc:NIAGENIngredientMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:IngredientsSegmentMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-3110550000 USD20240306Open filing evidence

NIAGEN Related · Analytical Reference Standards And Services Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdxc:NIAGENRelatedMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-310 USD20240306Open filing evidence

Other Goods And Services · Analytical Reference Standards And Services Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdxc:OtherGoodsAndServicesMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-312905000 USD20240306Open filing evidence

Other Ingredients · Analytical Reference Standards And Services Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdxc:OtherIngredientsMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-310 USD20240306Open filing evidence

Other Ingredients · Consumer Products Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdxc:OtherIngredientsMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:ConsumerProductsSegmentMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-310 USD20240306Open filing evidence

Other Ingredients · Ingredients Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdxc:OtherIngredientsMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:IngredientsSegmentMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-31587000 USD20240306Open filing evidence

Reference Standards · Analytical Reference Standards And Services Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdxc:ReferenceStandardsMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-312804000 USD20240306Open filing evidence

TRUNIAGEN Consumer Product · Analytical Reference Standards And Services Segment

Subsegments · Statement Business Segments

Source dimensions us-gaap:SubsegmentsAxis=cdxc:TRUNIAGENConsumerProductMember;us-gaap:StatementBusinessSegmentsAxis=cdxc:AnalyticalReferenceStandardsAndServicesSegmentMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-310 USD20240306Open filing evidence